Healthcare · NIFTY 500

Aurobindo Pharma Limited

NSEAUROPHARMA BSE524804 ISININE406A01037 SeriesEQ Listed on NSE · BSE

₹1,807.20 -20.30 (-1.11%) Updated 12 Nov, 9:19 pm IST

Open chart Back to screener

Price, daily close+56.64% in a year

Today

Open: ₹1,813.10
Prev close: ₹1,827.50
Day high: ₹1,821.10
Day low: ₹1,785.40
Volume: 22.75 L
Value traded: ₹410.20 Cr
Upper circuit: ₹1,861.60
Lower circuit: ₹1,753.20
52W high: ₹1,807.20
52W low: ₹1,106.00
1 month: +9.42%
6 months: +21.08%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹103,986 Cr

P/E (TTM)26.21

P/B2.64

Book value / share₹684.74

EPS (TTM)₹68.96

ROE10.1%

Dividend yield0.39%

Dividend (12m)₹7.00 / share

Net margin (TTM)10.8%

Operating margin21.0%

Debt / equity0.21

Current ratio1.73

EV / EBITDA14.21

Sales growth (YoY qtr)+23.87%

Profit growth (YoY qtr)+32.72%

Sales CAGR 3Y+10.63%

Profit CAGR 3Y+22.05%

Shares57.54 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

7,352936

Dec 23

7,580909

Mar 24

7,567919

Jun 24

7,796817

Sep 24

7,979855

Dec 24

8,382903

Mar 25

7,868825

Jun 25

8,286848

Sep 25

8,646910

Dec 25

8,853921

Mar 26

9,1501,033

Jun 26

10,2631,126

Sep 26

Revenue · QoQ (vs last quarter)

—+3.1%-0.2%+3.0%+2.3%+5.1%-6.1%+5.3%+4.3%+2.4%+3.4%+12%

Revenue · YoY (vs a year ago)

————+8.5%+11%+4.0%+6.3%+8.4%+5.6%+16%+24%

Net profit · QoQ (vs last quarter)

—-2.9%+1.2%-11%+4.6%+5.7%-8.7%+2.9%+7.3%+1.2%+12%+9.1%

Net profit · YoY (vs a year ago)

————-8.7%-0.6%-10%+3.8%+6.5%+2.0%+25%+33%

RevenueNet profitLine = trend

16.04

Dec 23

15.51

Mar 24

15.69

Jun 24

14.00

Sep 24

14.56

Dec 24

15.56

Mar 25

14.20

Jun 25

14.61

Sep 25

15.67

Dec 25

15.86

Mar 26

17.86

Jun 26

19.57

Sep 26

EPS (₹) · YoY (vs a year ago)

————-9.2%+0.3%-9.5%+4.4%+7.6%+1.9%+26%+34%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	7,352	7,580	7,567	7,796	7,979	8,382	7,868	8,286	8,646	8,853	9,150	10,263
Other income	163	136	221	136	157	135	105	121	188	117	264	168
Total income	7,514	7,716	7,788	7,932	8,136	8,517	7,973	8,406	8,834	8,970	9,415	10,432
Raw material	2,676	2,635	2,467	2,742	2,729	2,800	2,535	2,510	2,755	2,505	2,894	2,980
Purchases	776	786	680	747	824	636	808	846	893	931	932	914
Employee cost	990	1,026	1,072	1,109	1,132	1,163	1,229	1,277	1,310	1,374	1,480	1,659
Other expenses	1,610	1,820	1,803	1,910	1,954	2,000	1,797	1,991	2,081	2,298	2,162	2,466
Total expenses	6,249	6,351	6,463	6,725	6,938	7,150	6,769	7,132	7,430	7,677	7,858	8,741
Operating profit	1,601	1,551	1,620	1,566	1,578	1,792	1,603	1,678	1,708	1,753	1,841	2,156
OPM %	21.8%	20.5%	21.4%	20.1%	19.8%	21.4%	20.4%	20.3%	19.8%	19.8%	20.1%	21.0%
Finance cost	75.6	89.4	111	113	118	115	97.8	95.2	92.8	98.2	102	102
Depreciation	423	354	404	382	419	444	406	429	465	479	487	531
Exceptional items	—	-122	—	—	—	—	—	—	-65.3	—	-40.2	—
Profit before tax	1,265	1,243	1,325	1,207	1,198	1,367	1,205	1,274	1,338	1,293	1,517	1,691
Tax	322	323	406	391	354	432	383	428	429	370	483	564
Net profit	940	907	918	817	846	903	824	848	910	921	1,032	1,124
Profit to shareholders	936	909	919	817	855	903	825	848	910	921	1,033	1,126
EPS (₹)	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86	19.57

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

16,5003,7720.0

FY18

23,0994,7982,831

FY20

24,7758,1485,339

FY21

23,4554,2592,648

FY22

24,8553,7191,928

FY23

29,0025,6513,173

FY24

31,7246,5833,486

FY25

33,6536,7803,505

FY26

Revenue · YoY (vs a year ago)

——+7.3%-5.3%+6.0%+17%+9.4%+6.1%

Net profit · YoY (vs a year ago)

——+89%-50%-27%+65%+9.9%+0.5%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY18	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	16,500	23,099	24,775	23,455	24,855	29,002	31,724	33,653
Other income	102	86.2	381	320	291	557	622	492
Total expenses	13,364	19,400	20,571	20,244	22,522	24,970	27,248	28,970
Employee cost	2,131	3,219	3,535	3,451	3,522	3,923	4,476	5,190
Operating profit	3,772	4,798	8,148	4,259	3,719	5,651	6,583	6,780
OPM %	22.9%	20.8%	32.9%	18.2%	15.0%	19.5%	20.8%	20.1%
Finance cost	77.7	160	74.5	48.6	140	290	457	384
Depreciation	558	967	1,055	1,127	1,245	1,522	1,649	1,778
Profit before tax	3,238	3,758	7,399	3,404	2,624	4,397	5,098	5,110
Tax	818	914	2,010	726	685	1,211	1,583	1,609
Tax rate %	25.3%	24.3%	27.2%	21.3%	26.1%	27.5%	31.0%	31.5%
Net profit	2,423	2,830	5,334	2,647	1,928	3,169	3,484	3,503
Profit to shareholders	0.0	2,831	5,339	2,648	1,928	3,173	3,486	3,505
Net margin %	0.0%	12.3%	21.5%	11.3%	7.8%	10.9%	11.0%	10.4%
EPS (₹)	41.36	48.32	91.04	45.19	32.90	54.16	59.81	60.34

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

26,8404,8624,396

Mar 23

29,8436,3153,393

Mar 24

32,6537,9425,569

Mar 25

37,8917,6767,191

Mar 26

39,4008,2346,232

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+11%+9.4%+16%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	26,840	29,843	32,653	37,891	39,400
Long-term borrowings	619	2,135	1,562	803	982
Short-term borrowings	4,243	4,180	6,380	6,873	7,252
Total borrowings	4,862	6,315	7,942	7,676	8,234
Current liabilities	11,494	12,199	14,682	18,039	19,667
Fixed assets (PPE)	7,995	11,546	12,189	14,330	15,292
Inventories	8,511	9,808	10,544	12,053	13,124
Trade receivables	4,466	4,817	5,746	7,094	7,544
Cash & equivalents	4,396	3,393	5,569	7,191	6,232
Current assets	21,546	23,772	27,162	32,709	33,959
Total assets	39,890	45,072	49,785	58,502	61,754
Debt / equity	0.18	0.21	0.24	0.20	0.21

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

5,016-3,215-2,969

FY22

2,387-3,9781,814

FY23

2,435-4,256800

FY24

3,925-1,875120

FY25

5,526-3,458-1,269

FY26

Operations · YoY (vs a year ago)

—-52%+2.0%+61%+41%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	5,016	2,387	2,435	3,925	5,526
Cash from investing	-3,215	-3,978	-4,256	-1,875	-3,458
Cash from financing	-2,969	1,814	800	120	-1,269
Spent on fixed assets	-2,053	-2,404	-2,780	-1,968	-2,686
Free cash flow	2,964	-17.1	-346	1,957	2,841
Net cash flow	-1,168	223	-1,021	2,169	799

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

51.8%Dec 23

51.8%Mar 24

51.8%Jun 24

51.8%Sep 24

51.8%Dec 24

51.8%Mar 25

51.8%Jun 25

51.8%Sep 25

51.8%Dec 25

51.8%Mar 26

51.9%Jun 26

51.9%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

51.9%promoter

Promoter & group: 51.88%
Public (FIIs, mutual funds, retail…): 48.12%
Promoter change, last quarter: 0.00 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Interim Dividend - Rs 7 Per ShareEx 11-Nov-2026
Buy BackEx 17-Apr-2026
Interim Dividend - Rs 4 Per ShareEx 08-Aug-2025
Annual General MeetingEx 26-Aug-2024
Buy BackEx 30-Jul-2024
Interim Dividend - Rs 1.50 Per ShareEx 20-Feb-2024
Interim Dividend - Rs 3 Per ShareEx 20-Nov-2023
Annual General MeetingEx 22-Aug-2023

Board meetings

the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.04-Nov-2026
the financial results for the period ended September 30, 2026 and dividend04-Nov-2026
AUROBINDO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 05-Aug-2026 to inter-alia consider and approve the Unaudited Fin…05-Aug-2026
the financial results for the period ended Jun 30, 202605-Aug-2026
the financial results for the period ended March 31, 202621-May-2026

Filings with NSE

General Updates11 Nov
Analysts/Institutional Investor Meet/Con. Call Updates11 Nov
General Updates11 Nov
Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Analysts/Institutional Investor Meet/Con. Call Updates9 Nov
Copy of Newspaper Publication6 Nov
Change in Director(s)4 Nov

Latest news

Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and historyYahoo Finance Singapore · 10 Nov, 11:56 pm Aurobindo Pharma shares extend losses after USFDA's OAI classification for subsidiary's plant - CNBC TV18LinkedIn · 12 Nov, 2:14 pm Aurobindo Pharma shares extend losses after USFDA's OAI classification for subsidiary's plantCNBC TV18 · 12 Nov, 12:37 pm News by CNBC TV18 on TradingView, 2026-11-12 — cnbctv:fcdb8e742094b:0TradingView · 12 Nov, 12:37 pm Buzzing stocks: Bajaj Finance, Tata Power, Adani Enterprises, Sandur Manganese, Alivus Life, Aurobindo PharmaBusinessLine · 12 Nov, 7:32 am Missed Aurobindo Pharma's Run? Here's The Holders' CaseSimply Wall St · 12 Nov, 6:59 pm Stocks to Watch Today: Bajaj Finance, Tata Power, Mishra Dhatu Nigam, Aurobindo Pharma, ITC, Aditya...Moneycontrol.com · 12 Nov, 1:51 am Pharma stocks rally: Aurobindo, Divi's, Glenmark, Symbiotec hit new highsBusiness Standard · 6 Nov, 3:15 pm

About

About Aurobindo Pharma Limited

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Aurobindo Pharma Limited
NSE symbol: AUROPHARMA
BSE scrip code: 524804
ISIN: INE406A01037
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 19 Jul 2000
Face value: ₹1 per share
Market lot: 1 share
Shares issued: 57.54 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Other
Managing director / CEO: K. Nithyananda Reddy
Chair: Mangalam Ramasubramanian Kumar
Headquarters: Hyderabad, Telangana, India
Registered address: Galaxy, Floor 22-24; Plot No 1, Sy No 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad - 500032, Telangana, India
Founded: 1986
Employees: 46,455
Financial year: April to March
Results basis: Consolidated
Website: aurobindo.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Aurobindo Pharma Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers